Sciele Pharma and Plethora Solutions Announce Positive Phase III … – PR-Inside.com (Pressemitteilung)
Nov.09, 2008 in
News
|
Sciele Pharma and Plethora Solutions Announce Positive Phase III …
PR-Inside.com (Pressemitteilung), Austria - European Phase III double-blind placebo-controlled study of PSD502 for the treatment of premature ejaculation ('PE') has met its three co-primary endpoints … |
Similar Posts:
- Small caps round-up: Ten Alps/BT, Monitise, Plethora… – ShareCast
- Sciele Pharma and Plethora Solutions Announce Positive Phase III … – Business Wire (press release)
- Plethora premature ejaculation drug meets goals – Reuters UK
- Sciele Pharma and Plethora Solutions Announce Final Analysis of … – MarketWatch
- Sciele Pharma and Plethora Solutions Announce Final Analysis of … – UroToday
Leave a Reply